medigraphic.com
Órgano Oficial de el Colegio Mexicano de Urología

2003, Number 2

<< Back Next >>

Bol Col Mex Urol 2003; 18 (2)

Prophylactic treatment of the superficial bladder cancer (Ta-T1) with BCG. Comparative study between low dose (10 mg) and standard dose (50 mg)

García TVX, García PV, Preciado PF, Cabrera PC

Language: Spanish
References: 33
Page: 61-66
PDF size: 109.67 Kb.


ABSTRACT

Bladder cancer occupies the second place in frequency between urinary tumors, from the 76 to 90% they appear as superficial injuries (Ta-T1) and potentially curable. Recurrences varies from 30% for the unique tumors of low degree, to 90% implant manifold of high degree. Utility of the bladder application of BCG iS well-known like prophylactic treatment of the recurrences in the superficial bladder cancer. Complications by the bladder application of BCG are also well known, these are reported in 60 to 90% of the patients, these, 20% are severe. Some authors have tried to diminish the adverse effects with low doses of BCG in to the bladder without results. We made a comparative study in 76 patients with superficial bladder cancer, who received prophylactic treatment with BCG. Two groups formed, 36 patients received 50 mg of BCG per dose and 40 received 10 m, we compare the prophylactic effectiveness and complications in both groups. We applied a scheme of treatment with 6 weekly doses and 12 monthly; in recurrence cases, a second cycle was applied. Results: The global effectiveness for number of cycles applied was 66.6 and 63.2% and for the number of patients was 83 and 90% for both groups of 50 and 10 mg of BCG respectively, without statistic difference. The complications in the group of 50 mg was of 70% and these 12% were severe, in the10 mg group only 12% presented display low cystitis, with a statistically difference very significant. Conclusions: The 10 mg had the same effect that the 50 mg doses with less complications and secondary effects.


REFERENCES

  1. Neal D, Sharples L, Smith K. The epidemical growth factor receptor and the prognosis of bladder cancer. Cancer 1990; 65: 1619-1621.

  2. Lutzayer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1982; 127(2): 250-252.

  3. Flamm J, Donas S. The significance of bladder quadrant biopsies in patients with primary superficial bladder cancer. Eur Urol 1989; 16: 81-85.

  4. Lamm, Donald L. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 1985; 134: 40-47.

  5. Morales A, Mickel J, Wilson J. Dose-response of Bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol 1992; 147: 340-343.

  6. Gohji K, Nomi M, Okamoto M, Takenaca A. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of bladder. Urology l999; 53(2): 308-313.

  7. Nomi M, OnoY, Fujii A. Results of transurethral resection plus adjuvant intravesical chemotherapy for superficial bladder cancer. Int J Urol 1998; 5(6): 534-539.

  8. Wites JA, Caris CT, Mungan NA, Wites WP. Results of a randomized phase III trial of sequential intravesical therapy with mitomicina C and Bacillus Calmette-Guerin versus mitomicina C alone in patients with superficial bladder cancer. J Urol l998; 160(5): 1671-1672.

  9. Segawa N, Iwamoto Y, Azuma H. Intravesical BCG therapy for superficial bladder cancer. Hinyokika Kiyo 1998; 44(9): 627-631.

  10. Jurincic-Winkler C, Engelmann, Klippel KF. Efficacy of local Bacillus Calmette-Guerin treatment in superficial bladder cancer relapsing under Keyhole-Limpet Hemocyanin immunotherapy. Zentralbl Bakteriol 1995; 282(4): 409-415.

  11. Glick SH, Howell LP, White RWD. Relationship of p53 and Bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol 1996; 155: 1754-1757.

  12. Ovesen H, Horn T, Steven K. Long-term efficacy of intravesical Bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J Urol 1997; 157: 1655-1659.

  13. Soloway MS, Briggman JV, Carpinito GA. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996; l56: 363-367.

  14. Stampfer DS, Carpinito GA, Rodríguez-Villanueva J. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998; 159: 394-398.

  15. Johnston B, Morales A, Emerson L. Rapid detection of bladder cancer: a comparative study of point of ca test. J Urol 1997; 158: 2098-2101.

  16. Coplen D, Marcus M, Myers J. Long term follow up of patients treated with 1 or 2, weeks courses of intravesical BCG, analysis of possible predictors of response free of tumor. J Urol 1990; 144: 652-657.

  17. Nadler R, Catalona W. Durability of the tumor free response for intra vesical BCG therapy. J Urol 1994; 152: 367-373.

  18. Onur O, Queliker R. Polyarthritis as complication of intravesical Bacillus Calmette-Guerin immunotherapy for bladder cancer. Clin Rheumatol 1999; 18(1): 74-76.

  19. De Diego A, Rogado MC, Prieto M. Disseminated pulmonary granulomas after intravesical Bacillus Calmette-Guerin immmunotherapy. Respiration 1997; 64(4): 304-306.

  20. Matei FM, Giovannelli V, Schepis L. Granulomatous prostatitis as collateral effect of intravesical immunotherapy with BCG. Arch Ital Urol Androl 1998; 70/4: 177-182.

  21. Guerra CE, Betts RF, Shilling JW. Mycobacterium bovis osteomyelitis involving a hip arthroplasty after intravesical Bacillus Calmette-Guerin immunotherapy. Clinic Infec Dis 1998; 27(3): 639-640.

  22. Martínez-Cáceres P, Rubio-Briones J, Vicente J. Prevesical and inguinal abscess following intravesical BCG instillation. Scand J Urol Nephrol 1998; 32(6): 409-410.

  23. Boccafoschi C, Montefiore F, Pavesi M. Late effects of intravesical BCG immunotherapy on bladder mucosa infiltrating lymphocytes: immunohistochemical study. Eur Urol 1995; 27(4): 334-338.

  24. Lamm DL, Van Der Meijden APM, Morales A. Incidence and treatment of complications of BCG intravesical therapy in superficial bladder cancer. J Urol 1992; 157: 596-598.

  25. Droller MJ, Waslsh PC. Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: it is safe. J Urol 1991; 134: 1115-1119.

  26. Xochipiltecatl M, García C, Gallet T. Experiencia conjunta del uso de dosis bajas de BCG cepa danesa en el tratamiento y la profilaxis del cáncer superficial de vejiga. Bol Col Mex Urol 1996; 13: 18-23.

  27. Zonana F, Rodríguez E. Terapia intravesical de BCG en cáncer superficial de vejiga recurrente. Rev Mex Urol 1992; 52: 2-5.

  28. Moyano CJL, Ortiz GA, Romero DA, Sánchez SE, Blanco VE, Arribas RJM, Castineiras FJ. The prevention of stage-T1 superficial bladder tumors with 27 Mg. of BCG. Arc Esp Urol 1999; 52(7): 760.

  29. Herr HW, Lamm DL. Management of superficial bladder cancer, in principles of genitourinary oncology. D Raghavan, et al. Editors. 1997, Lippincott-Raven: Philadelphia. p: 273.

  30. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19(3): 573-80.

  31. Yalcinkaya F, Kamis L. Prospective randomized comparison of intravesical BCG therapy with standard versus low dose in superficial bladder cancer. Int Urol Nephrol 1998; 30(6): 821.

  32. Takashi M, Wakai K. Evaluation of low dose intravesical BCG therapy for superficial bladder cancer. Int Urol Nephrol 1995; 27(6): 723-33.

  33. Pagano F, Bassi P. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 1995; 27(1): 19-22.




2020     |     www.medigraphic.com